Philips Supports the American Heart Association’s Efforts to Raise Awareness of Cardiovascular Implantable Electronic Device (CIED) Infections, Promote Guideline Adherence, and Improve Patient Survival Rates

- The American Heart Association’s multi-year initiative, supported by Philips, aims to bring forward the latest education and clinical data to increase awareness for providers and patients in the pursuit of guideline-driven CIED care

- Every year in the USA less than 30% of patients with CIED infections are treated properly in accordance with guidelines^1-3

Amsterdam, the Netherlands, 19 Jan 2022 – Royal Philips, a global leader in health technology, is supporting the American Heart Association’s multi-year effort to generate awareness among cross-disciplinary specialties and improve survival rates from cardiovascular implantable electronic device (CIED) infections.

With the support of Philips, the American Heart Association’s national CIED infection initiative will work with medical professionals across a variety of specialities to prevent and properly treat infections resulting from cardiovascular implantable electronic devices such as pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices.

Each year one million CIEDs are implanted worldwide and one in 20 of these patients will develop a CIED infection within three years.^4,5 Support of efforts by the American Heart Association follows similar efforts by Philips, like its ‘No Infection Left Behind’ initiative, which aims to advance education for healthcare providers to help accurately diagnose CIED infections and deliver timely care.

Patients diagnosed with CIED infections are often treated with antibiotics, which is not an effective treatment option – 50-100% of patients treated with antibiotics alone will experience an infection relapse.^6,7 Clinical practice guidelines recommend extraction for all patients with a definite CIED infection, including complete device and lead removal. Too often, healthcare professionals lack awareness and experience in CIED infection management, increasing the chance of a missed infection diagnosis and prolonging inappropriate treatment. It is estimated that in the USA more than 7,000 CIED patient lives are at risk each year due to improper treatment. Yet complete CIED extraction is proven safe and effective, especially at an earlier stage of infection, which can reduce mortality rates and long-term costs.^8,9

“CIED infection is a major public health problem with substantial morbidity and mortality,” said Jonathan Piccini, M.D., M.H.S., Director of Cardiac Electrophysiology section at the Duke Heart Center and the current chair of the American Heart Association Get With The Guidelines®-AFib quality improvement registry. “Despite the tremendous impact of these infections on patients and their loved ones, potential life-saving guideline recommended care is infrequently applied.”

“By supporting the American Heart Association, we have a significant opportunity to improve care for a large group of cardiovascular patients,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “At Philips, we want to support medical professionals and their efforts to follow guideline-directed care and decrease the complications and negative outcomes that too often follow CIED infections.”

“We are pleased to receive the support of Philips on this important effort to raise awareness for CIED infection care, reduce mortality rates among patients and improve guideline driven care of people living with CIED devices,” said Michele Bolles, Senior Vice President Quality, Outcomes Research & Analytics at the American Heart Association. “We know that patient outcomes improve when guideline-directed care is consistently provided. These efforts amplify the mission of the American Heart Association to help every person have the opportunity for a longer, healthier life.”

Learn more about CIED infection:

• Through Philips ELITE Academy & Deviceinfection.com Philips has made resources available including education materials, data, case studies and Lead Management solutions to help educate providers in CIED infections.
• Overcoming Barriers to Complete and Early Extraction for CIED Infection: A Narrative Review of the Epidemiological, Clinical and Economic Evidence. This presentation, recently presented at the AHA Scientific Sessions by Ami Sood, M.D. from Philips, provides an overview of the many barriers patients face in receiving optimal treatments including challenges with infection diagnosis, patient referral to extraction centers and negative misconceptions regarding extraction procedures.
• American Heart Association at heart.org
• If you are a patient seeking to learn more about managing your heart device and finding a lead extractor, visit the Heart Rhythm Society for CIED management

About Royal Philips

Royal Philips is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

References

¹Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ. Incidence, treatment intensity, and incremental annual expenditures for patients experiencing a cardiac implantable electronic device infection: Evidence from a large US payer database 1-year post implantation. Circ Arrhythm Electrophysiol. 2016;9(8):e003929. doi:10.1161/CIRCEP.116.003929

²Dai M, Cai C, Vaibhav V, Sohail MR, et al. Trends of Cardiovascular Implantable Electronic Device Infection in 3 Decades: A Population-Based Study. JACC Clin Electrophysiol. 2019;5(9):1071-1080. doi:10.1016/j.jacep.2019.06.016

³Data on File. CIED Infection Treatment Inadequate Adherence to Guidelines.

⁴Greenspon AJ. J Am Coll Cardiol 58:1001–1006.; Kremers MS, Heart Rhythm 2013; 10:e59.

⁵Cantillon D. JACC EP. 2017.

⁶del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest. 2003;124(4):1451-1459. doi:10.1378/chest.124.4.1451

⁷Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med. 2000;133(8):604-608. doi:10.7326/0003-4819-133-8-200010170-00011

⁸Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular
implantable electronic device infections. 2011;8(11):1678-1685. doi:10.1016/j.hrthm.2011.05.015

⁹Greenspon AJ, Eby EL, Petrilla AA, Sohail MR. Treatment patterns, costs, and mortality among Medicare beneficiaries
with CIED infection. Pacing Clin Electrophysiol. 2018;41(5):495-503. doi:10.1111/pace.13300